BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
9/23/2025 6:48:59 AM | Browse: 47 | Download: 45
 |
Received |
|
2025-03-04 07:46 |
|
Peer-Review Started |
|
2025-03-04 07:46 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2025-04-03 08:57 |
|
Revised |
|
2025-04-15 14:27 |
|
Second Decision |
|
2025-08-11 02:51 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2025-08-12 06:38 |
|
Articles in Press |
|
2025-08-12 06:38 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
2025-08-13 02:06 |
|
Typeset the Manuscript |
|
2025-09-11 01:05 |
|
Publish the Manuscript Online |
|
2025-09-23 06:48 |
| ISSN |
2218-4333 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Minireviews |
| Article Title |
Antibody-drug conjugates in metastatic urothelial cancer: Highway to heaven
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Alberto D’Angelo, Martina Catalano, Irene De Gennaro Aquino, Valeria Gangi and Giandomenico Roviello |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Giandomenico Roviello, Associate Professor, MD, PhD, Health Science, University of Florence, vialePieraccini, 6, florence 50139, Italy. giandomenico.roviello@unifi.it |
| Key Words |
Metastatic urothelial carcinoma; Antibody-drug conjugates; Enfortumab vedotin; Clinical efficacy |
| Core Tip |
Metastatic urothelial carcinoma (mUC) remains a challenging malignancy with poor prognosis despite advances in treatment. Platinum-based chemotherapy has been the standard, but its toxicity limits use in many patients. Immune checkpoint inhibitors have improved survival, yet most patients eventually progress. Antibody-drug conjugates (ADCs) represent a transformative approach, delivering cytotoxic agents directly to tumor cells while minimizing systemic toxicity. Enfortumab vedotin and sacituzumab govitecan have shown significant efficacy, even in heavily pretreated patients. Ongoing research aims to optimize ADC combinations and identify biomarkers for patient selection, paving the way for more personalized and effective mUC therapies. |
| Publish Date |
2025-09-23 06:48 |
| Citation |
<p>D’Angelo A, Catalano M, De Gennaro Aquino I, Gangi V, Roviello G. Antibody-drug conjugates in metastatic urothelial cancer: Highway to heaven. <i>World J Clin Oncol</i> 2025; 16(9): 106646</p> |
| URL |
https://www.wjgnet.com/2218-4333/full/v16/i9/106646.htm |
| DOI |
https://dx.doi.org/10.5306/wjco.v16.i9.106646 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
